CLINICAL TRIALS PROFILE FOR LITHOBID
✉ Email this page to a colleague
All Clinical Trials for Lithobid
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00183443 ↗ | Treatment of Mania Symptoms With Drug Therapy | Completed | National Institute of Mental Health (NIMH) | Phase 3 | 2005-02-01 | This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania. |
| NCT00183443 ↗ | Treatment of Mania Symptoms With Drug Therapy | Completed | Palo Alto Veterans Institute for Research | Phase 3 | 2005-02-01 | This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania. |
| NCT00408681 ↗ | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | Completed | National Cancer Institute (NCI) | N/A | 2006-06-01 | RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant. |
| NCT00408681 ↗ | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | Completed | Fred Hutchinson Cancer Research Center | N/A | 2006-06-01 | RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant. |
| NCT00601536 ↗ | Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions | Completed | Roxane Laboratories | N/A | 2003-04-01 | The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fasting conditions using a single-dose, randomized, 2 treatment, 2-period, 2-sequence crossover design. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lithobid
Condition Name
| Condition Name for Lithobid | |
| Intervention | Trials |
| Bipolar Disorder | 4 |
| Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | 2 |
| Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | 2 |
| Recurrent Adult Acute Myeloid Leukemia | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Lithobid
Trials by Country
Clinical Trial Progress for Lithobid
Clinical Trial Phase
Clinical Trial Sponsors for Lithobid
Sponsor Name
